WO1999012521A1 - New foam-forming pharmaceutical composition - Google Patents

New foam-forming pharmaceutical composition Download PDF

Info

Publication number
WO1999012521A1
WO1999012521A1 PCT/SE1998/001568 SE9801568W WO9912521A1 WO 1999012521 A1 WO1999012521 A1 WO 1999012521A1 SE 9801568 W SE9801568 W SE 9801568W WO 9912521 A1 WO9912521 A1 WO 9912521A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
composition according
foam
pharmaceutically active
active substance
Prior art date
Application number
PCT/SE1998/001568
Other languages
French (fr)
Inventor
Stefan Friess
Harald Heckenmüller
Heike Kublik
Olivier Szambien
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Priority to JP2000510420A priority Critical patent/JP2001515851A/en
Priority to US09/155,250 priority patent/US6258374B1/en
Priority to EP98943141A priority patent/EP1011636A1/en
Priority to AU90999/98A priority patent/AU731208B2/en
Priority to CA002302710A priority patent/CA2302710A1/en
Publication of WO1999012521A1 publication Critical patent/WO1999012521A1/en
Priority to IS5393A priority patent/IS5393A/en
Priority to NO20001160A priority patent/NO20001160L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention provides a pharmaceutical composition for rectal or vaginal administration and its use in therapy.
  • enemas are used to reach the lower part.
  • Enemas are usually used in the form of a foam to overcome the problem of leakage from the rectum following administration which makes it necessary for patients to lie down during administration.
  • Foams, as well as pessaries, tampons and creams are used to administer drugs to the vagina.
  • Conventional foams for rectal or vaginal administration are filled in pressurised containers with a pharmaceutically active ingredient dissolved or suspended in a liquid vehicle, at least one propellant gas and a surfactant with foaming properties.
  • a pharmaceutically active ingredient dissolved or suspended in a liquid vehicle
  • at least one propellant gas at least one propellant gas
  • a surfactant with foaming properties e.g., mesalazine, peppermint, sucralfate or budesonide
  • Examples based on mesalazine, peppermint, sucralfate or budesonide as the active ingredient dispersed in a liquid vehicle containing a foaming surfactant and administered for topical action in the colon using a pressurised atomiser with a propellant gas are described in EP-A-468 555.
  • Rectal foams formed by a propellant gas on expulsion from a pressurised container and containing other active ingredients such as flunisolide and its derivatives (see WO 94/12187), 5-aminosalicylic acid (EP 395 329), and 4-aminosalicylic acid (DE 4316724) have also been described.
  • Chlorofluorocarbons are generally used as the propellant gas but these are undesirable for environmental reasons.
  • pressurised containers to administer pharmaceutically active substances suffers from a number of problems. For example, it is difficult to administer an accurate dose of the pharmaceutical composition of the drug; the containers are difficult to store over long periods of time because of leakage of gas which results in reduced administration capacity.
  • disposal of used containers can be dangerous because of the risk of explosions on incineration. Accordingly alternative formulations need to be found.
  • composition for rectal or vaginal administration which comprises at least two parts wherein the composition comprises
  • the individual parts of the composition are mixed which causes the two or more substances defined in (i) to react to produce a gas which contacts the polymer stabiliser (ii) forming a water-soluble collapsible foam which may then be applied to the rectum or vagina.
  • the polymer stabiliser is preferably used in a swelled form, e.g. in the form of a hydrogel.
  • the composition of the invention is preferably administered from a multi-part syringe. The advantage of such a device is that the foaming action is smooth and the time for the administration is controllable using the piston of the syringe resulting in less discomfort for the patient.
  • the two or more substances defined in (i) are preferably one or more acids, especially water-soluble acids and one or more effervescent compounds. Each is generally used as an aqueous solution in a concentration of from 0.1 to 10 % by weight of the composition.
  • the acid is preferably hydrochloric acid or a water-soluble mono- or polycarboxylic acid.
  • suitable water-soluble mono- or polycarboxylic acids include citric, lactic, tartaric, succinic, glycollic, malonic, oxalic, malic, fumaric, maleic, or acetic acid.
  • citric acid preferably in a concentration of from 1 to 3% by weight of the composition.
  • the effervescent compound is preferably a pharmaceutically acceptable alkali metal carbonate or bicarbonate e.g. sodium monohydrogen carbonate, potassium monohydrogen carbonate, sodium carbonate or potassium carbonate. Most preferred is sodium monohydrogen carbonate, preferably in a concentration of from 3.5 to 5.5% by weight of the composition.
  • concentration of each substance to be used depends on the volume of foam required and the desired pH and osmolarity of the foam to be formed.
  • the two substances (i) are an acid and an effervescent compound, they should be used in a ratio of from 1 :0.5 to 1 :25, preferably from 1:1 to 1 :4, by weight of the acid to the effervescent compound.
  • the polymer stabiliser (ii) is preferably a hydrogel thickener.
  • the polymer stabiliser used in the invention preferably displays pseudoplastic flow characteristics when in solution. More preferably the polymer stabiliser used in the invention is a water soluble hydrogel thickening polymer, e.g. a natural polysaccharide, semi-synthetic polymer or a synthetic polymer, or a mixture thereof.
  • a water soluble hydrogel thickening polymer e.g. a natural polysaccharide, semi-synthetic polymer or a synthetic polymer, or a mixture thereof.
  • natural polysaccharides are agar, alginates, carrageenan, guar, arabic, fragacanth, pectins, dextran, gellan and xanthan gums.
  • Suitable semi-synthetic polymers are polysaccharide derivatives, e.g. cellulose esters and modified starches.
  • polymers examples include polyvinyl alcohol, polyvinylpyrrolidone, polyacrylates, polyvinylacetate, and poloxamer.
  • the viscosity of a solution thickened with the polymer stabiliser is remains substantially the same in a wide pH range and is relatively independent of ionic strength.
  • the polymer stabiliser is xanthan gum or hydroxyethyl cellulose.
  • the polymer stabiliser is xanthan gum.
  • xanthan gum has a low viscosity at high shear rates, therefore they are easy to pump, spray and spread. They exhibit a high viscosity at low shear rates. This results in a good stabilisation of suspended drugs.
  • the polymer stabiliser is preferably used in such concentrations that solutions or dispersions containing it in swelled form have a viscosity as measured by Bohlin® rotational viscosimeter CSR-lOa within the ranges shown in Table 1 at the given shear rates.
  • concentration of a given polymer stabiliser required to meet the viscosity requirements may easily be determined empirically by a person of skill in the art.
  • the concentration of the polymer stabiliser should be from 0.1 to 5% by weight of the composition where it is xanthan gum or hydroxyethyl cellulose.
  • concentration of xanthan gum used is from 0.5 to 2% by weight of the composition and the concentration of hydroxyethyl cellulose where it is hydroxyethyl cellulose 4000 is from 2 to 3% by weight of the composition.
  • the polymer stabiliser is PVP 90, it is preferably used in a concentration of from 5 to 30% by weight of the composition, preferably 10 to 25% by weight.
  • the pharmaceutically active substance to be used in the present invention depends on the disease to be treated by the composition or intended effect of the composition. It is preferably one or more of an anti-inflammatory drug, analgesic, local anaesthetic, anti- infection drugs, contraceptive and/or an anti-anginal agent.
  • Suitable anti-inflammatory drugs include steroids or non steroidal anti-inflammatory drugs (NSAIDs).
  • Preferred analgesics and local anaesthetics are lidocaine, morphine or codeine.
  • Preferred steroids are budesonide, suitable esters of beclomethasone, rofleponide or suitable derivatives (e.g.
  • esters thereof, hydrocortisone, betamethasone, prednisolone, dexamethasone, fluocinolone, amcinonide, bufexamac or flunisolide. Particularly preferred is budesonide.
  • Preferred NSAIDs are 4-aminosalicylic acid, 5-aminosalicylic acid or sulphasalazine.
  • Preferred anti-infection drugs are anti-microbial agents (e.g. bacitracin or iodine), antiseptics (e.g. cetrimide), fungicides (e.g. clotrimazole, metronidazole or cyclosporine) and anti-viral agents (e.g. acyclovir or idoxuridin).
  • Preferred anti-anginal agents are isosorbide-5-mononitrate or isosorbide dinitrate.
  • the pharmaceutically active substances can be administered alone or in combination.
  • the concentration of the pharmaceutically active substance to be used depends upon the intended volume of the foam to be produced by the composition on administration, the potency of the substance, the nature of the condition to be treated etc. and can easily be determined by a person of skill in the art.
  • the pH of the part of the composition comprising the pharmaceutically active substance and the pH of the foam resulting from mixing the two components depends upon the requirements for the stability of the pharmaceutically active substance incorporated therein.
  • the pH of the part containing it should be from 2 to 5.
  • the pH of the foam should be from 5 to 8, which is a physiologically well tolerated pH range.
  • the pharmaceutically active substance used in the present invention is suspended within one of the parts of the composition, it is preferably in micronised form. Preferably it has a particle size of below 20 ⁇ m in order to minimise the risk of sedimentation during storage of the composition and to facilitate the dispersion of the substance in the composition without decreasing the foam rigidity during administration.
  • composition according to the invention may optionally comprise pharmaceutically acceptable excipients such as surfactants, preservatives, and other types of stabilisers, for example antioxidants, chelating agents, tonicity modifiers (e.g. sodium chloride, mannitol, sorbitol or glucose), spreading agents and water soluble lubricants, e.g. propylene glycol, glycerol or polyethylene glycol.
  • pharmaceutically acceptable excipients such as surfactants, preservatives, and other types of stabilisers, for example antioxidants, chelating agents, tonicity modifiers (e.g. sodium chloride, mannitol, sorbitol or glucose), spreading agents and water soluble lubricants, e.g. propylene glycol, glycerol or polyethylene glycol.
  • concentration of each excipient required may easily be determined empirically by a person skilled in the art.
  • Suitable surfactants include ionic surfactants, e.g. lauryl sulphate, or non-ionic surfactants e.g. phospholipids, poloxamer, and polysorbate. Non-ionic surfactants are preferably used.
  • Suitable preservatives include benzalkonium chloride, parabens, chlorhexidine acetate, chlorhexidine gluconate, sorbic acid, potassium sorbitol, chlorbutanol and phenoxyethanol.
  • chelating agents such as EDTA or phosphates can be added.
  • Suitable spreading agents are those used for topical applications e.g. di-n-octyl ether (for example Cetiol® OE), fatty alcohol polyalkylene glycol ether (for example Aethoxal® B), 2-ethylhexyl palmitate (for example Cegesoft® C 24), and isopropyl fatty acid esters.
  • the spreading agent should preferably be dispersed in the same part as the polymer stabiliser.
  • composition of the invention is that since the gas used to form the foam is produced by reaction, the composition is under less pressure on administration which minimises the risk of inducing a defecation reaction reflex.
  • the composition according to the invention is such that it forms a foam which is collapsible.
  • the volume of the foam formed by the composition preferably is reduced by 50%) in from 2 to 120 minutes after administration and completely collapses to its original volume after 5 to 240 minutes.
  • the time before the foam collapses is preferably sufficiently long so that the foam spreads as far up the colon as possible but it is preferably not so long that it is removed from the area to be treated by the natural movement of the intestines before it has collapsed.
  • the collapse time depends on a number of factors. For example the greater the amount of gas produced by the two or more substances (i) or the higher the viscosity of the component comprising the polymer stabiliser, the longer the collapse time.
  • the collapse time also depends on the nature of the other additives to the composition which have surface active properties e.g. surfactants or preservatives.
  • the advantage of the collapsibility of the foam formed by the composition of the present invention is that removal of foam from the patient is more comfortable for the patient and there is less chance of the active substance being trapped in the centre of the foam and being unable to contact the area of the body to be treated.
  • the foam formed by the composition according to the invention is water-soluble because the composition is substantially free from water-insoluble di- or trivalent metal salts which could complex with the polymer stabiliser to make the foam insoluble.
  • the invention further provides the use of the composition according to the invention in the manufacture of a medicament for the treatment of disorders of the intestines, rectum or vagina.
  • the invention also provides a method of treatment or prophylaxis of disorders of the intestines, rectum or vagina which comprises administering a therapeutically effective amount of the composition according to the invention to a patient suffering from or liable to suffer from a said disorder.
  • a composition according to the invention comprising the components set out in Table 2 was prepared. It was then mixed to form a foam whose collapsibility was determined.
  • Component 1 was prepared by dissolving the citric acid, sodium edetate and poloxamer in purified water and dispersing xanthan and budesonide in the resulting solution. To hydrate the xanthan the dispersion was agitated at room temperature under vacuum for 30 minutes. The resulting hydrogel was filled into one chamber of a two chamber mixing syringe (MLXPAC System 50 manufactured by Mixpac Systems AG, Switzerland).
  • Component 2 was prepared by dissolving the sodium bicarbonate and sodium edetate in purified water and dispersing xanthan in the solution obtained by agitation at room temperature under vacuum for 30 minutes. The resulting alkaline hydrogel was filled in the other chamber of the two chamber syringe.
  • Both chambers of the syringe were connected with a mixing tip, in which thorough mixing of the two components took place upon discharging the chambers by a plunger.
  • the foam produced was filled into a measuring cylinder.
  • the volume of the expanded foam was measured and its collapse with time was monitored.
  • a composition according to the invention comprising the components set out in Table 3 was prepared. It was then mixed to form a foam whose collapsibility was determined.
  • Component 1 was prepared by dissolving the citric acid, sodium edetate, polysorbate 80 and lidocain in purified water and dispersing hydroxyethyl cellulose in the solution obtained. The dispersion was agitated under vacuum at room temperature for 3 hours. The resulting hydrogel was filled into one chamber of a two chamber mixing syringe as used in Example 1.
  • Component 2 was prepared by dissolving sodium bicarbonate in purified water and dispersing hydroxyethyl cellulose in the solution obtained by agitation at room temperature and vacuum for 3 hours. A foam was generated as described in Example 1.
  • the foam produced was filled into a measuring cylinder.
  • the volume of the expanded foam was measured and its collapse with time was monitored. 10 g of each component was used and it took 5 seconds to discharge the syringe. A volume of 86 ml was obtained 60 seconds after discharge. After 15 minutes the volume had decreased to 83 ml and after 30 minutes the volume had decreased to 69 ml. It took two hours before the foam collapsed completely.
  • the pH of the foam was 6.82.

Abstract

The invention provides a pharmaceutical composition for rectal ou vaginal administration which comprises at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabiliser which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance; and its use in a treatment or prophylaxis of disorders of the intestines, rectum or vagina.

Description

NEW FOAM-FORMING PHARMACEUTICAL COMPOSITION
Field of the invention
The present invention provides a pharmaceutical composition for rectal or vaginal administration and its use in therapy.
Background of the invention
Various means of administering drugs to the intestine are known. For example oral controlled release compositions are used to reach the upper part whereas enemas are used to reach the lower part. Enemas are usually used in the form of a foam to overcome the problem of leakage from the rectum following administration which makes it necessary for patients to lie down during administration. Foams, as well as pessaries, tampons and creams are used to administer drugs to the vagina.
Conventional foams for rectal or vaginal administration are filled in pressurised containers with a pharmaceutically active ingredient dissolved or suspended in a liquid vehicle, at least one propellant gas and a surfactant with foaming properties. Examples based on mesalazine, peppermint, sucralfate or budesonide as the active ingredient dispersed in a liquid vehicle containing a foaming surfactant and administered for topical action in the colon using a pressurised atomiser with a propellant gas are described in EP-A-468 555. Rectal foams formed by a propellant gas on expulsion from a pressurised container and containing other active ingredients such as flunisolide and its derivatives (see WO 94/12187), 5-aminosalicylic acid (EP 395 329), and 4-aminosalicylic acid (DE 4316724) have also been described.
Chlorofluorocarbons are generally used as the propellant gas but these are undesirable for environmental reasons. Also the use of pressurised containers to administer pharmaceutically active substances suffers from a number of problems. For example, it is difficult to administer an accurate dose of the pharmaceutical composition of the drug; the containers are difficult to store over long periods of time because of leakage of gas which results in reduced administration capacity. Furthermore the disposal of used containers can be dangerous because of the risk of explosions on incineration. Accordingly alternative formulations need to be found.
Description of the invention
According to the invention there is provided a pharmaceutical composition for rectal or vaginal administration which comprises at least two parts wherein the composition comprises
(i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabiliser which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance.
During administration the individual parts of the composition are mixed which causes the two or more substances defined in (i) to react to produce a gas which contacts the polymer stabiliser (ii) forming a water-soluble collapsible foam which may then be applied to the rectum or vagina. The polymer stabiliser is preferably used in a swelled form, e.g. in the form of a hydrogel. The composition of the invention is preferably administered from a multi-part syringe. The advantage of such a device is that the foaming action is smooth and the time for the administration is controllable using the piston of the syringe resulting in less discomfort for the patient.
The two or more substances defined in (i) are preferably one or more acids, especially water-soluble acids and one or more effervescent compounds. Each is generally used as an aqueous solution in a concentration of from 0.1 to 10 % by weight of the composition.
The acid is preferably hydrochloric acid or a water-soluble mono- or polycarboxylic acid. Examples of suitable water-soluble mono- or polycarboxylic acids include citric, lactic, tartaric, succinic, glycollic, malonic, oxalic, malic, fumaric, maleic, or acetic acid. Most preferred is citric acid, preferably in a concentration of from 1 to 3% by weight of the composition.
The effervescent compound is preferably a pharmaceutically acceptable alkali metal carbonate or bicarbonate e.g. sodium monohydrogen carbonate, potassium monohydrogen carbonate, sodium carbonate or potassium carbonate. Most preferred is sodium monohydrogen carbonate, preferably in a concentration of from 3.5 to 5.5% by weight of the composition. The exact concentration of each substance to be used depends on the volume of foam required and the desired pH and osmolarity of the foam to be formed. Generally where the two substances (i) are an acid and an effervescent compound, they should be used in a ratio of from 1 :0.5 to 1 :25, preferably from 1:1 to 1 :4, by weight of the acid to the effervescent compound.
The polymer stabiliser (ii) is preferably a hydrogel thickener. The polymer stabiliser used in the invention preferably displays pseudoplastic flow characteristics when in solution. More preferably the polymer stabiliser used in the invention is a water soluble hydrogel thickening polymer, e.g. a natural polysaccharide, semi-synthetic polymer or a synthetic polymer, or a mixture thereof. Examples of natural polysaccharides are agar, alginates, carrageenan, guar, arabic, fragacanth, pectins, dextran, gellan and xanthan gums. Suitable semi-synthetic polymers are polysaccharide derivatives, e.g. cellulose esters and modified starches. Examples of synthetic polymers are polyvinyl alcohol, polyvinylpyrrolidone, polyacrylates, polyvinylacetate, and poloxamer. Preferably the viscosity of a solution thickened with the polymer stabiliser is remains substantially the same in a wide pH range and is relatively independent of ionic strength. More preferably the polymer stabiliser is xanthan gum or hydroxyethyl cellulose. Most preferably the polymer stabiliser is xanthan gum.
The advantage of xanthan gum is that compositions containing it have a low viscosity at high shear rates, therefore they are easy to pump, spray and spread. They exhibit a high viscosity at low shear rates. This results in a good stabilisation of suspended drugs. The polymer stabiliser is preferably used in such concentrations that solutions or dispersions containing it in swelled form have a viscosity as measured by Bohlin® rotational viscosimeter CSR-lOa within the ranges shown in Table 1 at the given shear rates. The concentration of a given polymer stabiliser required to meet the viscosity requirements may easily be determined empirically by a person of skill in the art.
Table 1
Figure imgf000006_0001
In general the concentration of the polymer stabiliser should be from 0.1 to 5% by weight of the composition where it is xanthan gum or hydroxyethyl cellulose. Preferably the concentration of xanthan gum used is from 0.5 to 2% by weight of the composition and the concentration of hydroxyethyl cellulose where it is hydroxyethyl cellulose 4000 is from 2 to 3% by weight of the composition. When the polymer stabiliser is PVP 90, it is preferably used in a concentration of from 5 to 30% by weight of the composition, preferably 10 to 25% by weight.
The pharmaceutically active substance to be used in the present invention depends on the disease to be treated by the composition or intended effect of the composition. It is preferably one or more of an anti-inflammatory drug, analgesic, local anaesthetic, anti- infection drugs, contraceptive and/or an anti-anginal agent. Suitable anti-inflammatory drugs include steroids or non steroidal anti-inflammatory drugs (NSAIDs). Preferred analgesics and local anaesthetics are lidocaine, morphine or codeine. Preferred steroids are budesonide, suitable esters of beclomethasone, rofleponide or suitable derivatives (e.g. esters) thereof, hydrocortisone, betamethasone, prednisolone, dexamethasone, fluocinolone, amcinonide, bufexamac or flunisolide. Particularly preferred is budesonide. Preferred NSAIDs are 4-aminosalicylic acid, 5-aminosalicylic acid or sulphasalazine. Preferred anti-infection drugs are anti-microbial agents (e.g. bacitracin or iodine), antiseptics (e.g. cetrimide), fungicides (e.g. clotrimazole, metronidazole or cyclosporine) and anti-viral agents (e.g. acyclovir or idoxuridin). Preferred anti-anginal agents are isosorbide-5-mononitrate or isosorbide dinitrate. The pharmaceutically active substances can be administered alone or in combination.
The concentration of the pharmaceutically active substance to be used depends upon the intended volume of the foam to be produced by the composition on administration, the potency of the substance, the nature of the condition to be treated etc. and can easily be determined by a person of skill in the art.
The pH of the part of the composition comprising the pharmaceutically active substance and the pH of the foam resulting from mixing the two components depends upon the requirements for the stability of the pharmaceutically active substance incorporated therein. For example, when the pharmaceutically active substance is budesonide, the pH of the part containing it should be from 2 to 5. At the time of administration of the composition of the invention, the pH of the foam should be from 5 to 8, which is a physiologically well tolerated pH range.
If the pharmaceutically active substance used in the present invention is suspended within one of the parts of the composition, it is preferably in micronised form. Preferably it has a particle size of below 20 μm in order to minimise the risk of sedimentation during storage of the composition and to facilitate the dispersion of the substance in the composition without decreasing the foam rigidity during administration.
The composition according to the invention may optionally comprise pharmaceutically acceptable excipients such as surfactants, preservatives, and other types of stabilisers, for example antioxidants, chelating agents, tonicity modifiers (e.g. sodium chloride, mannitol, sorbitol or glucose), spreading agents and water soluble lubricants, e.g. propylene glycol, glycerol or polyethylene glycol. The concentration of each excipient required may easily be determined empirically by a person skilled in the art.
Suitable surfactants include ionic surfactants, e.g. lauryl sulphate, or non-ionic surfactants e.g. phospholipids, poloxamer, and polysorbate. Non-ionic surfactants are preferably used.
Suitable preservatives include benzalkonium chloride, parabens, chlorhexidine acetate, chlorhexidine gluconate, sorbic acid, potassium sorbitol, chlorbutanol and phenoxyethanol.
In order to improve the stability of the pharmaceutically active substance chelating agents such as EDTA or phosphates can be added.
Suitable spreading agents are those used for topical applications e.g. di-n-octyl ether (for example Cetiol® OE), fatty alcohol polyalkylene glycol ether (for example Aethoxal® B), 2-ethylhexyl palmitate (for example Cegesoft® C 24), and isopropyl fatty acid esters. The spreading agent should preferably be dispersed in the same part as the polymer stabiliser.
One advantage of using the composition of the invention is that since the gas used to form the foam is produced by reaction, the composition is under less pressure on administration which minimises the risk of inducing a defecation reaction reflex.
The composition according to the invention is such that it forms a foam which is collapsible. The volume of the foam formed by the composition preferably is reduced by 50%) in from 2 to 120 minutes after administration and completely collapses to its original volume after 5 to 240 minutes. The time before the foam collapses is preferably sufficiently long so that the foam spreads as far up the colon as possible but it is preferably not so long that it is removed from the area to be treated by the natural movement of the intestines before it has collapsed. The collapse time depends on a number of factors. For example the greater the amount of gas produced by the two or more substances (i) or the higher the viscosity of the component comprising the polymer stabiliser, the longer the collapse time. The collapse time also depends on the nature of the other additives to the composition which have surface active properties e.g. surfactants or preservatives.
The advantage of the collapsibility of the foam formed by the composition of the present invention is that removal of foam from the patient is more comfortable for the patient and there is less chance of the active substance being trapped in the centre of the foam and being unable to contact the area of the body to be treated.
The foam formed by the composition according to the invention is water-soluble because the composition is substantially free from water-insoluble di- or trivalent metal salts which could complex with the polymer stabiliser to make the foam insoluble.
The invention further provides the use of the composition according to the invention in the manufacture of a medicament for the treatment of disorders of the intestines, rectum or vagina. The invention also provides a method of treatment or prophylaxis of disorders of the intestines, rectum or vagina which comprises administering a therapeutically effective amount of the composition according to the invention to a patient suffering from or liable to suffer from a said disorder.
The present invention is further illustrated by the following examples which should not be interpreted as limiting the scope of the invention.
Example 1
A composition according to the invention comprising the components set out in Table 2 was prepared. It was then mixed to form a foam whose collapsibility was determined. Component 1 was prepared by dissolving the citric acid, sodium edetate and poloxamer in purified water and dispersing xanthan and budesonide in the resulting solution. To hydrate the xanthan the dispersion was agitated at room temperature under vacuum for 30 minutes. The resulting hydrogel was filled into one chamber of a two chamber mixing syringe (MLXPAC System 50 manufactured by Mixpac Systems AG, Switzerland).
Component 2 was prepared by dissolving the sodium bicarbonate and sodium edetate in purified water and dispersing xanthan in the solution obtained by agitation at room temperature under vacuum for 30 minutes. The resulting alkaline hydrogel was filled in the other chamber of the two chamber syringe.
Both chambers of the syringe were connected with a mixing tip, in which thorough mixing of the two components took place upon discharging the chambers by a plunger.
The foam produced was filled into a measuring cylinder. The volume of the expanded foam was measured and its collapse with time was monitored.
10 g of each component was used and it took 10 seconds to discharge the syringe. A volume of 95 ml was obtained 5 seconds after discharge. After 5 minutes the volume had decreased to 90 ml, and after 10 minutes the volume had decreased to 85 ml. It took two and half hours before the foam collapsed completely. The pH of the foam was 6.28.
Table 2
Figure imgf000011_0001
* Keltrol® RD, Kelco, Hamburg ** Lutrol® F68
Example 2
A composition according to the invention comprising the components set out in Table 3 was prepared. It was then mixed to form a foam whose collapsibility was determined.
Component 1 was prepared by dissolving the citric acid, sodium edetate, polysorbate 80 and lidocain in purified water and dispersing hydroxyethyl cellulose in the solution obtained. The dispersion was agitated under vacuum at room temperature for 3 hours. The resulting hydrogel was filled into one chamber of a two chamber mixing syringe as used in Example 1.
Component 2 was prepared by dissolving sodium bicarbonate in purified water and dispersing hydroxyethyl cellulose in the solution obtained by agitation at room temperature and vacuum for 3 hours. A foam was generated as described in Example 1.
The foam produced was filled into a measuring cylinder. The volume of the expanded foam was measured and its collapse with time was monitored. 10 g of each component was used and it took 5 seconds to discharge the syringe. A volume of 86 ml was obtained 60 seconds after discharge. After 15 minutes the volume had decreased to 83 ml and after 30 minutes the volume had decreased to 69 ml. It took two hours before the foam collapsed completely. The pH of the foam was 6.82.
Table 3
Figure imgf000012_0001
* Tylose H 4000 PHA ** Polysorbate 80

Claims

Claims
1. A pharmaceutical composition for rectal or vaginal administration which comprises at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabiliser which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance.
2. A composition according to claim 1 wherein the two or more substances defined in (i) are one or more acids and one or more effervescent compounds.
3. A composition according to claim 2 wherein the acid is a water-soluble acid.
4. A composition according to claim 1 , 2 or 3 wherein the polymer stabiliser is a hydrogel thickener.
5. A composition according to any one of the preceding claims wherein the pharmaceutically active substance is one or more of an anti-inflammatory drug, analgesic, local anaesthetic, anti-infection drugs, contraceptive and/or a vaso-active drug.
6. A multi-part syringe comprising a composition according to any one of the preceding claims.
7. Use of a composition according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of disorders of the intestines, rectum or vagina.
8. A method of treatment or prophylaxis of disorders of the intestines, rectum or vagina which comprises administering a therapeutically effective amount of a composition according to any one of claims 1 to 5 to a patient suffering from or liable to suffer from a said disorder.
PCT/SE1998/001568 1997-09-08 1998-09-03 New foam-forming pharmaceutical composition WO1999012521A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000510420A JP2001515851A (en) 1997-09-08 1998-09-03 New foam-forming pharmaceutical compositions
US09/155,250 US6258374B1 (en) 1997-09-08 1998-09-03 Foam-forming pharmaceutical composition
EP98943141A EP1011636A1 (en) 1997-09-08 1998-09-03 New foam-forming pharmaceutical composition
AU90999/98A AU731208B2 (en) 1997-09-08 1998-09-03 New foam-forming pharmaceutical composition
CA002302710A CA2302710A1 (en) 1997-09-08 1998-09-03 New foam-forming pharmaceutical composition
IS5393A IS5393A (en) 1997-09-08 2000-03-02 New foaming formulation
NO20001160A NO20001160L (en) 1997-09-08 2000-03-07 New foam-forming pharmaceutical preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703226A SE9703226D0 (en) 1997-09-08 1997-09-08 New pharmaceutical composition
SE9703226-2 1997-09-08

Publications (1)

Publication Number Publication Date
WO1999012521A1 true WO1999012521A1 (en) 1999-03-18

Family

ID=20408171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/001568 WO1999012521A1 (en) 1997-09-08 1998-09-03 New foam-forming pharmaceutical composition

Country Status (9)

Country Link
US (1) US6258374B1 (en)
EP (1) EP1011636A1 (en)
JP (1) JP2001515851A (en)
AU (1) AU731208B2 (en)
CA (1) CA2302710A1 (en)
IS (1) IS5393A (en)
NO (1) NO20001160L (en)
SE (1) SE9703226D0 (en)
WO (1) WO1999012521A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en) * 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6867199B2 (en) * 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
KR100906574B1 (en) * 2001-09-04 2009-07-10 다우 글로벌 테크놀로지스 인크. Process for dispersing a fluid in solid particles
KR100933625B1 (en) * 2001-09-04 2009-12-24 다우 글로벌 테크놀로지스 인크. Aqueous air foam, agglomeration method and coating method of solid particles using the same
CN1203055C (en) 2001-09-26 2005-05-25 朱德煦 Method and composition for treating or preventing bacterial infection
DK1572169T3 (en) * 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Detection and modulation of Slit and Robo-mediated angiogenesis and applications thereof
CA2480099C (en) 2002-03-26 2019-01-08 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004037225A2 (en) 2002-10-25 2004-05-06 Foamix Ltd. Cosmetic and pharmaceutical foam
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2005027851A2 (en) * 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8030362B2 (en) * 2003-12-12 2011-10-04 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
US8211449B2 (en) * 2004-06-24 2012-07-03 Dpt Laboratories, Ltd. Pharmaceutically elegant, topical anhydrous aerosol foam
US20060147504A1 (en) * 2004-12-30 2006-07-06 Bobby Corry Feminine anti-itch cloth
US8252308B2 (en) * 2005-01-27 2012-08-28 C.B. Fleet Company Inc. Feminine anti-itch gel
JP2008540511A (en) 2005-05-09 2008-11-20 フォーミックス エルティーディー． Sugar foaming composition
CN1869002A (en) * 2005-05-27 2006-11-29 中国科学院上海药物研究所 Class I non-steroid androgen acceptor regulator, its preparation method and use
JP5184373B2 (en) * 2006-01-19 2013-04-17 ディスファー・インターナショナル・ベー・フェー Foam composition
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US8445226B2 (en) 2010-02-01 2013-05-21 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US9273286B2 (en) 2010-06-13 2016-03-01 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP2891712A4 (en) 2012-07-23 2016-04-06 Inst Biophysics Cn Acad Sci Method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro
CN104884077B (en) 2012-10-08 2019-02-12 上海泽生科技开发股份有限公司 The component and method for treating diabetic's heart failure
ES2743617T3 (en) 2013-05-22 2020-02-20 Zensun Shanghai Science & Tech Co Ltd Prolonged release of neuregulin to treat heart failure
EP3035903B1 (en) 2013-08-20 2018-08-22 Anutra Medical, Inc. Syringe fill system and method
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN113289002A (en) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 Methods and compositions for the prevention, treatment or delay of heart failure using neuregulin
US11447687B2 (en) 2020-09-29 2022-09-20 Saudi Arabian Oil Company Enhancing rheological properties of foam using aloe-barbadensis gel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153836A2 (en) * 1984-02-29 1985-09-04 Health Products Development Inc. Dry, water-foamable pharmaceutical compositions
US5089606A (en) * 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599082A (en) * 1984-08-13 1986-07-08 Becton, Dickinson And Company Two-component syringe assembly
DE3674483D1 (en) * 1985-06-27 1990-10-31 Duphar Int Res MULTI-CHAMBER SYRINGE.
US4613326A (en) * 1985-07-12 1986-09-23 Becton, Dickinson And Company Two-component medication syringe assembly
US4929230A (en) * 1988-09-30 1990-05-29 Pfleger Frederick W Syringe construction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153836A2 (en) * 1984-02-29 1985-09-04 Health Products Development Inc. Dry, water-foamable pharmaceutical compositions
US5089606A (en) * 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications

Also Published As

Publication number Publication date
SE9703226D0 (en) 1997-09-08
NO20001160D0 (en) 2000-03-07
IS5393A (en) 2000-03-02
AU9099998A (en) 1999-03-29
AU731208B2 (en) 2001-03-29
NO20001160L (en) 2000-05-08
EP1011636A1 (en) 2000-06-28
US6258374B1 (en) 2001-07-10
CA2302710A1 (en) 1999-03-18
JP2001515851A (en) 2001-09-25

Similar Documents

Publication Publication Date Title
AU731208B2 (en) New foam-forming pharmaceutical composition
JP4880657B2 (en) Improved drug delivery to mucosal surfaces
JP4199306B2 (en) Aqueous foamable composition
AU762677B2 (en) Prolonged release bioadhesive vaginal gel dosage form
CN102429862B (en) Sustained-release povidone iodine eye drops
US20120129819A1 (en) Gel compositions for administration of pharmaceutically active compounds
JP5651279B2 (en) Methods for the treatment of endometriosis
JPH08508280A (en) Nasal pharmaceutical composition containing luteinizing agent
CA2315782A1 (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant
OA10950A (en) Aqueous-based pharmaceutical composition
CN102258785B (en) Slow-release drug carrier
CN101983723A (en) Slow-release medicine carrier
MXPA06009094A (en) Controlled release formulations.
CN102000339A (en) Drug carrier capable of realizing sustained release of drug
WO1992014473A1 (en) Steroid formulations
JP5979466B2 (en) Viscous liquid composition
JP2729859B2 (en) Reversible thermogelling aqueous pharmaceutical composition
CN115605183A (en) Composition for treating and/or preventing vestibular pain
MXPA00006161A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09155250

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998943141

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 90999/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2302710

Country of ref document: CA

Ref country code: CA

Ref document number: 2302710

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998943141

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 90999/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998943141

Country of ref document: EP